Lomerizine

Drug Profile

Lomerizine

Alternative Names: DE-090; KB 2796; Lomerizine hydrochloride; Migsis

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Nippon Organon; Pfizer
  • Developer Merck & Co; MSD KK; Pfizer; Santen Pharmaceutical
  • Class Antimigraines; Eye disorder therapies; Piperazines; Vasodilators
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II Glaucoma
  • Discontinued Cerebral infarction

Most Recent Events

  • 03 Sep 2015 Phase-II development for Glaucoma is ongoing in Japan
  • 13 May 2009 Lomerizine is still in phase II development for glaucoma in Japan
  • 04 Dec 2007 Lomerizine is still in phase II development for glaucoma in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top